Business
IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology
CAESAREA, Israel, April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of
About this update from Icecure Medical Ltd.
[{"type":"text","content":"CAESAREA, Israel, April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it hosted three key ProSense® System events at the European Conference on Interventional Oncology (ECIO) from April 24 to 27, 2022 in Vienna, Austria.\n\n \n \n \n \n \n \n\n \nThe ProSense® System is an effective Liquid Nitrogen (LN2) cryoablation solution, capable of creating large lethal zones for optimal tumor destruction with a rapid cooling rate and stable ultra-cold temperatures (-160°C +/- 10°C).\nIceCure Industry Symposium: Liquid Nitrogen Based Cryoablation for Optimal Tumor Destruction\nOn April 25, Professor Franco Orsi, MD, PhD of the European Institute of Oncology in Milan, Italy moderated the IceCure Industry Symposium: Liquid Nitrogen Based Cryoablation for Optimal Tumor Destruction. Professor Orsi provided a concise overview and rationale for performing cryoablation procedures followed by case studies from Dr. Yair Halpern of Bnei Zion Medical Center, Haifa, Israel on renal cancer cryoablation and from Dr. Ghizlane Touimi Benjelloun of CHU de Nîmes, France on cryoablation of adrenal gland and vertebral metastasis.\nScientific Presentation: Cryoablation of Low-Risk Breast Cancer An Update of the ICE3 Trial\nDr. Kenneth R. Tomkovich, Co-Primary Investigator of the ICE3 trial, presented promising interim data on cryoablation of small, low-risk breast cancers on April 26. The interim results were originally published on April 29, 2021 and show almost 98% of patients who received ProSense® System cryoablation treatment are recurrence free, with one-third of patients having reached 5 years post-treatment. No significant device-related adverse events were reported with no scarring or change in shape and size of the breasts and 98% of doctors and 95% of patients reported satisfaction with the cosmetic results.\nThe ICE3 trial was designed to evaluate the safety and efficacy of breast cryoablation with IceCure's ProSense® System, enabling women older than 60 with low-risk early-stage breast cancers to benefit from a non-surgical treatment and avoid the associated surgical risks. The study, which enrolled 194 eligible pati...